These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 27261196)

  • 1. Inhibition of hyaluronic acid formation sensitizes chronic myelogenous leukemia to treatment with doxorubicin.
    Uchakina ON; Ban H; Hostetler BJ; McKallip RJ
    Glycobiology; 2016 Nov; 26(11):1171-1179. PubMed ID: 27261196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronic Acid Inhibitor 4-Methylumbelliferone Activates the Intrinsic Apoptosis Pathway in K562 Chronic Myelogenous Leukemia Cells.
    Ban H; Uchakina O; McKallip RJ
    Anticancer Res; 2015 Oct; 35(10):5231-40. PubMed ID: 26408682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting hyaluronic acid production for the treatment of leukemia: treatment with 4-methylumbelliferone leads to induction of MAPK-mediated apoptosis in K562 leukemia.
    Uchakina ON; Ban H; McKallip RJ
    Leuk Res; 2013 Oct; 37(10):1294-301. PubMed ID: 23876826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Methylumbelliferone Suppresses Hyaluronan Synthesis and Tumor Progression in SCID Mice Intra-abdominally Inoculated With Pancreatic Cancer Cells.
    Nagase H; Kudo D; Suto A; Yoshida E; Suto S; Negishi M; Kakizaki I; Hakamada K
    Pancreas; 2017 Feb; 46(2):190-197. PubMed ID: 27846148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
    Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotinamide increases the sensitivity of chronic myeloid leukemia cells to doxorubicin via the inhibition of SIRT1.
    Pan S; Leng J; Deng X; Ruan H; Zhou L; Jamal M; Xiao R; Xiong J; Yin Q; Wu Y; Wang M; Yuan W; Shao L; Zhang Q
    J Cell Biochem; 2020 Jan; 121(1):574-586. PubMed ID: 31407410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptotic Effects of Some Tetrahydronaphthalene Derivatives on K562 Human Chronic Myelogenous Leukemia Cell Line.
    Koc A; Ozkan T; Hekmatshoar Y; Gurkan-Alp AS; Aktan F; Buyukbingol Z; Sunguroglu A; Buyukbingol E; Karabay AZ
    Anticancer Agents Med Chem; 2018 Feb; 17(14):1924-1930. PubMed ID: 28403785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human leukemic cell lines synthesize hyaluronan to avoid senescence and resist chemotherapy.
    Lompardía SL; Papademetrio DL; Mascaró M; Álvarez EM; Hajos SE
    Glycobiology; 2013 Dec; 23(12):1463-76. PubMed ID: 24013961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.
    Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K
    Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
    Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines.
    Lompardía SL; Díaz M; Papademetrio DL; Pibuel M; Álvarez É; Hajos SE
    Invest New Drugs; 2017 Feb; 35(1):1-10. PubMed ID: 27718039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.
    Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L
    Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of apoptosis and erythroid differentiation of human chronic myelogenous leukemia K562 cells by low concentrations of lidamycin.
    Zhang C; Guo LY; Mu D; Gong JH; Chen J
    Oncol Rep; 2019 Jan; 41(1):475-482. PubMed ID: 30542729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells.
    Shi YQ; Qu XJ; Liao YX; Xie CF; Cheng YN; Li S; Lou HX
    Eur J Pharmacol; 2008 Apr; 584(1):66-71. PubMed ID: 18304528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway.
    Cai H; Li L; Jiang J; Zhao C; Yang C
    Phytother Res; 2019 Jun; 33(6):1683-1688. PubMed ID: 30937974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
    J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
    Li J; Xue L; Hao H; Han Y; Yang J; Luo J
    Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
    Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
    Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hyaluronic acid inhibitor 4-methylumbelliferone is an NSMase2 activator-role of Ceramide in MU anti-tumor activity.
    Qin J; Kilkus J; Dawson G
    Biochim Biophys Acta; 2016 Feb; 1861(2):78-90. PubMed ID: 26548718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.